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Background: There is no evidence from randomized trials for the beneﬁt of routine non-compliant balloon (NCB)
post-dilation after stent deployment. Despite being the gold standard, intravascular ultrasound is infrequently
performed due to time and cost constraints and a suitable alternative technology is required for routine
assessment of stent expansion. The purpose of this study was to assess the contribution of NCB post-dilation in
optimizing contemporary stents by using digital stent enhancement (DSE).
Methods:We treated 120 patientswith stent insertion and assessed the stentswith DSE before and after NCB use.
Optimal expansion was deﬁned as the minimum stent diameter (MSD)≥90% of the nominal stent diameter, an
adaptation of theMUSIC and POSTIT trial criteria. Stent deployment was performed at 12 atm pressure followed
by routine NCB post-dilation at ≥14 atm.
Results: The mean reference diameter on QCA was 2.75 mm (SD 0.63) and mean stent diameter was 3.15 mm
(SD 0.46). At a mean stent deployment pressure of 11.7 atm (SD 2.4), only 21% of stents were optimally expand-
ed. After NCB inﬂation at a mean of 16.9 atm (SD 2.8), MSD increased by 0.26 mm (SD 0.24), optimal stent ex-
pansion increased from 21% to 58% and mean stent symmetry ratio increased from 0.83 to 0.87 (p b 0.0001).
Conclusions: Contemporary stents are sub-optimally expanded in the majority of cases after standard deploy-
ment compared with nominal sizes. Adjunctive NCB post-dilation optimized an additional 37% of stents. DSE
analysis can assist in qualitative and quantitative stent assessments and can potentially facilitate a selective
NCB post-dilation strategy to achieve optimal stent expansion.
Crown Copyright © 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Optimal stent expansion and larger minimum stent area (MSA)
are powerful predictors of improved long-term patency and clinical
outcomes [1,2]. Coronary stents are commonly under-expanded
in vivo compared with nominal stent diameters [3,4] after standard
deployment. Stent deployment strategies vary among operators
from the use of moderate pressures (12–14 atm) versus high pressure
deployment (16–20 atm). The use of adjunctive non-compliant bal-
loons (NCB) also varies between operators and there are no randomized
controlled trials showing the beneﬁt from routine use. Consequently,
post-dilation remains at operators' discretion in clinical practice as
well as in large interventional trials. NCB post-dilation was performed
in 34% of Sirolimus-eluting stents in the E-SIRIUS trial and 45% ofart Institute, 40 Ruskin Street,
handrasekhar).
eliability and freedom from bias
Ireland Ltd. This is an open access artEverolimus and Paclitaxel-eluting stents in the SPIRIT IV trial [5,6].
Some of the new stent platforms have improved in-vitro expansion
and radial strength characteristics, but whether this will translate into
a reduced need for NCB is not known. Angiography is not sufﬁciently
accurate to determine which stents require post-dilation [7,8] and rou-
tine IVUS use is not feasible. Digital stent enhancement (DSE) provides
improved stent visibility for qualitative assessment and has shown
good correlation with IVUS for evaluation of stent diameter and area
[7,9,10]. Itmay therefore be a suitable alternative technology to routine-
ly assess contemporary stent expansion and assist with decisions
regarding post-dilation. We sought to study the contribution of NCB
post-dilation in optimizing expansion of current-generation stents
using DSE to analyze stent expansion.
2. Materials and methods
2.1. Patient population
Patients undergoing elective or semi-urgent PCI at The Canberra
Hospital, Australia were eligible for enrolment. We recruited 120icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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formed consent for the procedure. Patients with ST elevationmyocardi-
al infarction needing emergent PCI were excluded. There were no
angiographic exclusion criteria and both native and graft PCI cases
were included. The subjects were unselected but not consecutive due
to limitations on human resources to recruit all PCI patients. The study
protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by the institutional human
research committee.2.2. Interventional procedure
PCI was undertaken via femoral or radial access. Routine lesion pre-
dilation and intra-coronary nitroglycerin use were recommended follow-
ed by stent deployment at nominal pressure as per the manufacturers'
compliance chart or to a maximum deployment pressure of 12 atm to
reduce the risk of edge dissection. All stents were routinely post-dilated
with NCB to at least 14 atm. The choice of stent and NCB type, stent
size, NCB size and inﬂation time were at operator's discretion. DSE imag-
ing was performed before and after NCB inﬂation and further NCB
inﬂations could be performed at the operator's discretion. NCB used in
this study included NC Empira, Hiryu, Pantera LEO, NC Quantum Apex,
NC Sprinter, and NC Trek.2.2.1. Digital stent enhancement analysis
We used the StentBoost DSE system (Philips Medical Systems,
Nederland B.V., Best, The Netherlands). A short cine run of 2.7 s at
15 fps was acquired with the deﬂated NCB placed within the stent.
The software superimposes 40 images of the stent centered on the
balloon markers and generates a high resolution stent image which
is available for review within seconds. DSE images of the stent
were taken before and after NCB use in the same unforeshortened
view using collimators to reduce radiation exposure. Ofﬂine DSE
measurements were performed using auto-calibration from the
manufacturer's software which provides tools for magnifying the
enhanced stent image and tracing both stent edges. We traced the
outline of the stent edges along the outer silhouette on both sides.
The software then calculates the minimum, mean and maximum
stent diameters and percent diameter stenosis. These data are used
to calculate percent stent expansion and stent symmetry.Table 1
Baseline patient characteristics.
Characteristic N (%)
Age, mean (SD) years 63.84 (10.9)
Male 101 (84%)2.3. Angiographic analysis
Quantitative Coronary Angiography (QCA) measurements were
performed ofﬂine independently of DSE analysis using contrast-ﬁlled
guide catheters for calibration. Angiography was also used to assess
the degree of vessel calciﬁcation at the lesion as nil–mild or moderate–
severe [11]. All DSE and angiographic measurements were performed
by the same operator. A 10% random sample of DSE measurements
was repeated by an independent operator to assess for inter-observer
variability.Risk factors
Hypertension 82 (68.3%)
Diabetes mellitus 30 (25.0%)
Dyslipidemia 75 (62.5%)
Smoking 20 (16.6%)
Reformed smoker 51 (42.5%)
Family history of IHD 45 (37.5%)
BMI ≥ 30 (kg/m2) 59 (49.2%)
Procedure indication
Recent STEMI 12 (10.0%)
NSTEMI 49 (40.8%)
Unstable angina 6 (5.0%)
Stable angina 53 (44.2%)
IHD, ischemic heart disease; BMI, body mass index; STEMI, ST elevation
myocardial infarction; NSTEMI, non-ST elevation myocardial infarction.2.4. Endpoints
The primary endpoint of the study was the change in the minimum
stent diameter (MSD) after NCB post-dilation measured using DSE. The
secondary endpointwas optimal stent expansion, deﬁned asMSD≥90%
of the nominal stent diameter, which was a non-IVUS adaptation of the
MUSIC and POSTIT trial criteria [12,13]. We also assessed the change in
the radial stent symmetry post-NCB which was deﬁned as the mini-
mum/maximum stent diameter with a symmetry ratio ≥0.7 regarded
as optimal [12]. We further explored correlates of optimal stent expan-
sion before and after NCB use in current generation stents.2.5. Clinical outcomes
Procedural success was deﬁned as successful stenting of the lesion
with b10% angiographic residual stenosis and TIMI 3 ﬂow. Myocardial
infarction was deﬁned according to the third universal deﬁnition of MI
[14]. Major adverse cardiovascular event (MACE) outcomes of death,
myocardial infarction (MI), stroke and urgent target vessel revasculari-
zation (TVR) in-hospital and at 12 month follow-up were recorded.
Follow-up was by clinic review, phone or letter.
2.6. Statistical analysis
Based on the POSTIT trial [13], we hypothesized an increase in MSD
of 0.15mm(SD0.5)withNCBpost-dilation in current-generation stents
and it was calculated that a sample size of 102 patients would be re-
quired with 85% power to show this increase (alpha 0.05).We assumed
a 10% loss to analyses and enrolled a total of 120 patients.
In addition to descriptive statistics, DSE measurements before and
after NCB were compared using paired Student's t-tests. Categorical
data were compared using the Chi-square statistic. Logistic regression
analyses using the likelihood ratio method were performed to explore
correlates of sub-optimal stent expansion after deployment. Probabili-
ties of 0.05 or less were considered signiﬁcant. Inter-observer agree-
ment on a 10% random sub-sample was determined using intraclass
correlation assuming absolute agreement.
3. Results
We enrolled 120 patients in this studywith amean age of 63.8 years
(SD 10.9) and 84% were male. Indication for the procedure was acute
coronary syndrome in 56%. Baseline characteristics including risk
factors and procedure indication are outlined in Table 1. Lesion, device
and deployment properties are outlined in Table 2. Interventions were
performed on the left anterior descending/diagonal artery in 52% of
cases followed by the right coronary artery in 25%. Complex lesions
(B2/C type) accounted for 67.5% of cases according to the ACC/AHA
lesion classiﬁcation system and moderate or severe calciﬁcation was
noted in 40% of lesions. Drug eluting stents (DES) were used in 63%
of cases.
Stent measurements on DSE before and after NCB inﬂation are
shown in Table 3. The mean reference diameter on QCA was 2.75 mm
(SD 0.63) and mean stent diameter was 3.15 mm (SD 0.46). After
stent deployment to a maximum pressure of 12 atm, 21% of stents
achieved optimal expansion and 65% of stents achieved MSD ≥80% on
DSE analysis. Following NCB inﬂation at a mean pressure of 16.9 atm
(SD 2.8), the minimum stent diameter (MSD) increased by 0.26 mm
(SD 0.24) [2.61 mm (SD 0.05) to 2.88 mm (SD 0.48), p b 0.0001] and
Table 2
Lesion, device and deployment properties.
Characteristic N (%)
PCI artery
Circumﬂex 20 (16.6%)
Diagonal 5 (4.2%)
LAD 62 (51.6%)
RCA 30 (25.0%)
SVG 3 (25.0%)
Lesion type
A 6 (5.0%)
B1 33 (27.5%)
B2 61 (50.8%)
C 20 (16.7%)
Calciﬁcation
Nil–mild 72 (60.0%)
Moderate–severe 48 (40.0%)
Lesion QCA, mean (SD)
Reference diameter, mm 2.75 (0.63)
Minimum diameter, mm 0.98 (0.35)
Diameter stenosis, % 63 (13.2)
Stent type, BMS 45 (37.5%)
Integrity 4 (3.3%)
Kaname 12 (10.0%)
Multilink 8 14 (11.6%)
Omega 15 (12.5%)
Stent type, DES 75 (62.5%)
Promus Element 21 (17.5%)
Resolute Integrity 21 (17.5%)
Xience Prime 33 (27.5%)
Stent and NCB properties Mean (SD)
Stent diameter, mm 3.15 (0.46)
Stent length, mm 18.05 (6.49)
Stent deployment pressure, atm 11.7 (2.4)
Stent deployment time, s 27 (8.6)
NCB diameter, mm 3.37 (0.52)
NCB deployment pressure, atm 16.85 (2.81)
NCB deployment time, s 26.5 (8.0)
LAD, left anterior descending artery; RCA, right coronary artery; SVG, saphenous vein
graft; QCA, quantitative coronary angiography; BMS, bare metal stent and DES, drug
eluting stent; NCB, non-compliant balloon.
Table 4
Correlates of sub-optimal expansion after stent deployment.
Factor Suboptimal expansion
N (%)
Odds ratio
(95% CI)
p
Factor present Factor absent
LAD/D lesion 58 (87%) 37 (70%) 2.80 (1.12–6.96) 0.025
B2/C lesion 69 (84%) 32 (71%) 2.87 (1.16–7.11) 0.022
Heavy calciﬁcation 43 (90%) 52 (72%) 3.31 (1.15–9.55) 0.017
Stent type: DES 63 (84%) 32 (71%) 2.13 (0.87–5.21) 0.10
Suboptimal expansion refers to MSD b90% of nominal stent diameter. LAD/D, left
anterior descending or diagonal artery; B2/C, lesion type based on AHA/ACC lesion
classiﬁcation; heavy calciﬁcation refers to moderate–severe calciﬁcation (see the
Materials and methods section).
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percentage expansion increased from 83.1% (SD 9.8) to 91.6% (SD 8.5)
(p b 0.0001). The proportion of stentswith optimal expansion following
NCB increased from 21% to 58% (p b 0.0001) and 89.16% stents achieved
MSD ≥80% of the nominal stent diameter. The stent symmetry
increased from a mean of 0.83 (SD 0.09) pre-NCB to a mean of 0.87
(SD 0.06) post-NCB (p b 0.0001).
There was strong inter-observer agreement in DSE measurements
before and after NCB inﬂation (pre-NCB, intraclass correlation 0.97,
95% CI = 0.9–0.99; post-NCB, 0.96, 95% CI = 0.86–0.99).
Table 4 shows the incidence of sub-optimal stent expansion in
various subsets. Correlates of sub-optimal stent expansion after stent
deployment, on univariate analysis included LAD/diagonal lesion loca-
tion (p = 0.025), B2/C lesion type (p = 0.022) and moderate–severe
calciﬁcation (p = 0.017). The mean percent nominal expansion
for DES was signiﬁcantly lower than for bare metal stents (BMS)Table 3
DSE Stent measurements before and after non-compliant balloon inﬂation.
Characteristic Pre-NCB
Mean (SD)
Post-NCB
Mean (SD)
p
Minimum stent diameter, mm 2.61 (0.50) 2.88 (0.48) b0.0001
Mean diameter, mm 2.88 (0.50) 3.10 (0.49) b0.0001
Diameter stenosis, % 5.98 (9.5) 4.5 (6.8) 0.001
Mean stent expansion, % 83.1 (9.8) 91.6 (8.5) b0.0001
Optimal expansion, % 21 58 b0.0001
Mean stent symmetry 0.83 (0.09) 0.87 (0.06) b0.0001
DSE, digital stent enhancement; NCB, non-compliant balloon.(81% versus 86%, p 0.018) after standard stent deployment. DSE
images and DSE software analysis are shown in Figs. 1–3.
Procedural success rate was 100%. In-hospital MACE was 2.5%
including 1 death post-operatively from heart failure and 2 peri-
procedural MI. Patients were followed for a mean of 389 days apart
from 4 patients who could not be contacted. One patient died from
lung cancer. Repeat angiography was performed in 15 patients
(13%) for clinical indications of whom 1 required repeat PCI and 1
underwent CABG.
4. Discussion
In this study we used digital stent enhancement (DSE) as a novel
tool to evaluate the contribution of NCB post-dilation in optimal expan-
sion of contemporary baremetal and drug eluting stents.We found that
the minimum stent diameter (MSD) increased by a mean of 0.26 mm
and the rate of optimal stent expansion from 21% to 58% following
routine NCB post-dilation and this was associated with good clinical
outcomes at 12 months. While the accuracy of DSE in stent analysis
has previously been shown, this study documents the feasibility of
using DSE technology in clinical practice to identify underexpanded
stents and facilitate stent optimization with NCB post-dilation [7,9,10].
4.1. Strategies for optimal stent deployment
There are no published guidelines on techniques for optimal stent
deployment and no evidence for a routine post-dilation strategy from
randomized trials. Some operators deploy stents at 16–20 atm, others
deploy stents at moderate pressures of 12–14 atm followed by routine
use of high pressure NCB post-dilation, while still others deploy stents
at moderate pressures and use visual assessment with angiography to
decide on the need for post-dilation. High pressure stent deployment
using the stent delivery system incurs the risk of “dog-boning”, edge
dissection and edge restenosis [15]. It is also thought to be a possible
contributor to late malapposition in DES, from damage to normal vessel
wall contiguous to stent and delayed healing from the drug [16]. On the
other hand, there is a better likelihood of uniform and controlled expan-
sion using a NCB at high pressure as the dilating force is focal to the
lesion. This is the rationale for stent deployment at moderately high
pressures (12–14 atm) followed by post-dilation with a shorter NCB
which we employed in this study [15]. Our study used DSE measure-
ments to document the adequacy of stent expansion using this deploy-
ment strategy. One small IVUS study has shown superior DES expansion
with high pressure NCB when compared with stent balloon post-
dilation [17].
4.2. Prevalence and implications of stent underexpansion
Incidence of stent underexpansion after standard deployment is
around 20–30% for both BMS [3,18] and DES [19] and is a consequence
of semi-compliant balloon (SCB) under-expansion against calciﬁed or
ﬁbrotic lesions or vessel recoil [20]. In a study of second generation
Fig. 1. Digital stent enhancement images and software analysis before and after non-compliant balloon post-dilation. 1a—3.0 × 16 mm stent deployed at 12 atm. 1b and 1c—Software
analysis tracing stent outline to measure minimum stent diameter at 1.66 mm. 2a—Stent after 3.5 mm non-compliant balloon post-dilation to 16 atm. 2b and 2c—Software analysis
measuring minimum stent diameter at 2.39 mm.
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24.6% of stents achieved ≥80% of nominal stent diameters at pres-
sures recommended by the manufacturers' charts [4]. At moderate
deployment pressures in our study, we found that 21% of stents
achieved≥90% and 65% of all stents achieved≥80% of nominal diame-
ters. Therefore despite improvements in stent balloon technologies in
recent years, suboptimal expansion following standard deployment
remains common.
Stent underexpansion has been shown to be associated with an
increased incidence of in-stent restenosis, stent thrombosis, TLR and
MACE at up to 12 months [1,21–23]. The recently reported AVIO ran-
domized study of IVUS versus angiography guided stent deployment
in complex lesions showed a 0.25 mm larger MSD in the IVUS group
although no difference in clinical outcomes was detected up to 2 years
[24]. In the larger ADAPT-DES trial, IVUS guidance was associated withFig. 2. Digital stent enhancement images before and after non-compliant balloon post-dilation
LAD artery across diagonal branch which also has a guidewire in place. The measured minim
2.76 mm, stent symmetry ratio 0.87, and nominal stent expansion 80%. 2—Stent after 3.0 mm
was 2.85 mm, mean stent diameter 3.03, maximum stent diameter 3.13 mm, stent symmetrya 0.2 mm larger maximum vessel diameter and a lower incidence of
stent thrombosis, TVR and MACE at 12 months compared to angio-
graphic guidance. Larger stents, larger balloons or higher inﬂation pres-
sures were used in the IVUS guidance group and minimizing stent
underexpansion is likely to have been a signiﬁcant factor in improved
outcomes in this group [25]. However, although desirable, IVUS imaging
is not feasible for every case due to economic and time constraints [26].
DSE may prove to be a useful inexpensive alternative to assess stent
expansion and judge the need for post-dilation.
4.3. Impact of non-compliant balloon post-dilation
In the POSTIT trial, the use of NCB at a mean of 13.8 atm increased
optimal expansion in an additional 22% of stents. In our study at a
mean of 16.9 atm, NCB optimized an additional 37% of all stents. It isin the main branch of a bifurcation lesion. 1—3.0 × 16mm stent deployed at 12 atm in the
al stent diameter was 2.4 mm, mean stent diameter 2.65 mm, maximum stent diameter
non-compliant balloon post-dilation to 20 atm. The measured minimal stent diameter
ratio 0.91, and nominal stent expansion 95%.
Fig. 3.Digital stent enhancement images before and after non-compliant balloon post-dilation for assessment of stent expansion and symmetry. 1—3.0 × 20mmstent deployed at 12 atm.
Themeasuredminimal stent diameterwas 2.17mm,mean stent diameter 2.52mm,maximumstent diameter 2.77mm, stent symmetry ratio 0.78, and nominal stent expansion 72.33%. 2
—Stent after 3.0 mm non-compliant balloon inﬂation to 20 atm. The measured minimal stent diameter was 2.7 mm, mean stent diameter 3.03 mm, maximum stent diameter 3.25 mm,
stent symmetry ratio 0.83, and nominal stent expansion 90%.
47J. Chandrasekhar et al. / IJC Heart & Vessels 3 (2014) 43–48not knownhoweverwhetherNCBpost-dilation should be advocated se-
lectively in sub-optimally expanded stents or routinely in all stents. The
concern with routine use of NCB apart from time and economic consid-
erations is that it can be associated with myocardial injury as indicated
by a rise in serum troponin. In the recent TWENTE trial post-dilation
was encouraged and was performed in 82% of stents. This may have
contributed to a higher incidence of peri-proceduralMI (4.1%), although
the 12 month clinical target lesion revascularization (TLR) rates were
lower (2.1%) compared to historic controls [27]. In our study with man-
dated post-dilation, only 1.6% had a peri-procedural MI. Additional data
are required to investigate the association of post-dilationwith troponin
elevation and long term outcomes post-PCI. The routine use of digital
stent enhancement to select cases for adjunctive post-dilation may
potentially reduce the incidence of myocardial injury.
4.4. Predictors of stent expansion
On exploratory analyses, we found that correlates for sub-optimal
stent expansion following standard deployment were LAD/diagonal le-
sion location, complex lesion type and moderate to severe calciﬁcation.
The mean percent nominal expansion for DES was signiﬁcantly lower
than for BMS (81.0% versus 86%) after routine stent deployment. This
may be related to physical characteristics of different stent platforms
and also the lesions being treated. The small nature of our study does
not allow deﬁnitive conclusions to be drawn from these ﬁndings.
4.5. Use of DSE for assessment of stent expansion
Digital stent enhancement has shown a good correlation with IVUS
for measurement of stent diameter and area [7,9] and can be used for
a rapid assessment of stent expansion in every case. With automatic
software analysis, it can assist with measurement of the minimum
stent diameter, stent expansion and symmetry, thereby potentially
facilitating an informed decision for the need to post-dilate. The tech-
nology is safe and user friendly at no added cost. Once operators became
familiar with the technique of DSE analysis, the time taken for analysis
per stent was under 1 min. DSE can also assist with correct stent place-
ment in case of overlapping stents, bifurcations and in identiﬁcation of
strut fracture [28,29]. Stentboost guided PCI has recently been shown
by Oh et al. to be associated with lower 12 month TLR and MACE rates
compared with angiography alone [30]. Given these results and the
high proportion of stents that are sub-optimally expanded following
standard deployment, we suggest the use of DSE to assess stent
expansion and to guide post-dilation strategy.4.6. Limitations of DSE
DSE provides only 2D assessment of stent geometry in a single
projection. Acquisition must therefore be obtained in the best
unforeshortened view. DSE does not provide information on vessel
wall, dissection and stent malapposition. In case of long stents and
tortuous vessels, more than one DSE run may be required to obtain
clear images of different segments of the stent. Sternal wires and
othermetallic objects in the ﬁeld of view could interferewith the recog-
nition of balloon markers by the software producing distorted images.
DSE imaging can increase the cumulative radiation dose per case and
operators need to be vigilant about the potential radiation risk. Our
mean procedural estimated effective dose was 15.75 mSv (SD 11.63)
which is comparable with the reference level of 15 mSv quoted for PCI
procedures by the ACC/AHA Advisory Committee [31]. This is despite
the fact that 56% of our cases included diagnostic angiography prior to
intervention. Recent data from Jin et al. showed that with sufﬁcient
operator experience and optimal radiation protection, Stentboost sub-
tract imaging did not signiﬁcantly increase patient radiation dose [32].
In our study, DSE measurements were performed ofﬂine. It is envis-
aged that future studies would investigate whether intra-operative
quantitative DSE assessment can facilitate more objective post-dilation
strategies to optimize stent expansion.
4.7. Study limitations
This was a single center non-randomized study thatwas powered to
detect a change in stent expansionwithNCB post-dilation.We observed
signiﬁcant correlations and some trends with various lesion and stent
characteristics that may affect stent expansion. These are hypothesis-
generating observations that merit further investigation in future
studies. We did not set out to evaluate our DSE ﬁndings with IVUS as
several recent studies have shown a good correlation between the two
technologies for MSD. DSE imaging was assessed in a single projection
and stent under-expansion in an orthogonal plane may not have
been detected.
5. Conclusions
Contemporary stents are commonly sub-optimally expanded after
standard deployment. Non-compliant balloon post-dilation increased
the minimum stent diameter by a mean of 0.26 mm and the rate of
optimal stent expansion from 21% to 58% which was associated with a
low 12 month MACE rate. LAD/diagonal lesions, complex lesions and
48 J. Chandrasekhar et al. / IJC Heart & Vessels 3 (2014) 43–48those with moderate to severe calciﬁcation as well as drug eluting
stents were associated with higher sub-optimal stent expansion rates
with standard deployment. Digital stent enhancement has the potential
for rapid qualitative and quantitative stent assessments to facilitate a
selective rather than routine post-dilation strategy.
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